
Texas Tech University Health Sciences Center, El Paso, TX

Harvard Medical School
Dana-Farber Cancer Institute
Brigham and Women's Hospital
WHO5 TP53 allelic state configuration is relevant in patients with TP53 mutated myeloid neoplasms receiving hypomethylating agent (HMA)-based regimens: Interim report of the International TP53 investigators Network (iTIN)